Jubilant Pharmova Limited has informed the Exchange about General Updates
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jubilant Pharmova's Canadian contract manufacturing facility (CMO Montreal), operated through Jubilant HollisterStier General Partnership (JHSGP), has received an 'Official Action Indicated' (OAI) classification from the USFDA following an audit conducted in October-November 2025. OAI is the most serious USFDA inspection classification and typically means regulatory action such as a warning letter or import alert may follow. The company says it has already implemented robust remediation measures and resumed production at the facility in Q4 FY26. JHSGP has stated it is working closely with the USFDA to address the observations. The facility is a key part of Jubilant's global CDMO (Contract Development and Manufacturing) business, offering sterile injectable, ophthalmic, and lyophilized product manufacturing services.
This is a negative development as an OAI classification could lead to further regulatory action (such as a warning letter or import alert), potentially impacting business from the Montreal facility and overall CDMO revenues. However, the resumption of operations and ongoing remediation suggest management is actively managing the situation. Shareholders should watch for any further USFDA action and monitor quarterly CDMO segment performance for impact.